Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. by Haglund, C. et al.
Br. J. Cancer (1986) 53, 189-195
Gastrointestinal cancer-associated antigen CA 19-9 in
histological specimens of pancreatic tumours and pancreatitis
C. Haglund1, J. Lindgren2, P.J. Roberts1 and S. Nordling3
1Fourth Department ofSurgery, Helsinki University Central Hospital; 2Department ofBacteriology and
Immunology; 3Department ofPathology, University ofHelsinki, Helsinki, Finland.
Summary The expression of the gastrointestinal cancer associated antigen CA 19-9, defined by the
monoclonal antibody 1116NS 19-9, was studied by immunoperoxidase staining in routine formalin-fixed,
paraffin-embedded tissue sections from normal pancreata, pancreata with pancreatitis and from benign and
malignant pancreatic neoplasms. The formalin-fixed specimens were treated with pepsin, which enhanced the
staining intensity. Eighty-five per cent of well to moderately differentiated adenocarcinomas were positive.
The staining was most intense in the apical border of cells lining the lumina of malignant glands, and in
mucus inside the lumina, but cytoplasmic staining was also seen. In poorly differentiated adenocarcinomas the
number of positive cells was smaller and in anaplastic carcinomas only occasional cells were stained. All
mucinous cystadenomas and cystadenocarcinomas stained intensely, whereas serous cystadenomas, and all
benign and malignant islet cell tumours were negative. Ducts in chronic pancreatitis and in normal pancreata
were positive in 96% and 79%, respectively, but the staining was focal and usually weaker than in
carcinomas. In acute pancreatitis (92% positive) the staining was more intense, and the CA 19-9 expression
was seen predominantly in small terminal ducts and in centroacinar cells. There was an apparent correlation
between the degree of differentiation of the ductal adenocarcinomas and the expression of CA 19-9, whereas
the correlation between tissue expression and serum levels ofCA 19-9 was poor.
The mouse monoclonal antibody 1116NS 19-9 was
developed by Koprowski et al. (1979) by the
hybridoma technique (Kohler & Milstein, 1975)
after immunizing mice with a human colorectal
cancer cell line, SW 1116. The antibody reacts with
a monosialoganglioside antigen, CA 19-9, which
corresponds to a sialylated Lewisa blood group
substance (Magnani et al., 1981, 1982). Originally
the antigen was believed to be expressed only in
colorectal carcinoma and in meconium and was
thought to be of oncofoetal nature (Magnani et al.,
1982).
Elevated concentrations of the CA 19-9 antigen
have been found in sera of patients with various
gastrointestinal cancers, whereas the serum levels of
healthy individuals are low (Koprowski et al., 1981,
Herlyn et al., 1982, Del Villano et al., 1983;
Jalanko et al., 1984; Kuusela et al., 1984; Ritts et
al., 1984). The serum CA 19-9 concentrations have
been shown to be highest in patients with
pancreatic cancer (Del Villano et al., 1983; Jalanko
et al., 1984; Haglund et al., 1986).
Immunohistochemically CA 19-9 can be detected
in colorectal cancer and in several other gastro-
intestinal carcinomas, and in non-neoplastic
epithelia from pancreas, stomach, liver and gall-
bladder. In addition, a smaller proportion of other
neoplastic and non-neoplastic tissues express
CA 19-9 (Atkinson et al., 1982; Arends et al.,
1983).
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In the present study we investigated the
expression of the CA 19-9 antigen immunohisto-
chemically in benign and malignant pancreatic
lesions using the biotin-avidin enhanced immuno-
peroxidase technique. The correlation between
tissue expression and serum concentration of
CA 19-9 was also studied.
Materials and methods
Specimens
Specimens were studied from 29 samples of normal
pancreatic tissue, 22 of which resection surfaces
from pancreata with cancer or chronic pancreatitis;
12 pancreata with acute and 23 with chronic
pancreatitis; 55 adenocarcinomas of exocrine origin
(45 primary tumours and 10 metastatic tumours),
all apparently ductal; five anaplastic carcinomas,
eight cystadenomas, three cystadenocarcinomas,
and 10 neoplasms of endocrine origin. In all but
four patients the samples were formalin-fixed,
paraffin-embedded surgical specimens, stored for
from two months to 10 years. Three samples of
normal pancreas and one adenocarcinoma were
examined from fresh organ specimens, snapfrozen
in liquid nitrogen, whereas both frozen and
formalin-fixed, paraffln-embedded sections were
available from six patients with a ductal adeno-
carcinoma.
Antibodies
Tissue culture supernatants containing mouse
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monoclonal antibodies 1116NS 19-9 (IgG1)
(Koprowski et al., 1979), CO-51.4 (IgG3) against
the Lewisa blood group determinant and CO-43.1
(IgM) against the Lewisb determinant (Blaszczyk et
al., 1983) were a kind gift from Dr Hilary
Koprowski (The Wistar Institute, Philadelphia, PA,
USA). Another mouse monoclonal antibody against
Uukuniemi virus (IgGj) (Dr Mikko Hurme,
Department of Bacteriology and Immunology,
University of Helsinki, Finland) was used as a
negative control.
Staining procedure
Five gm thick paraffin sections were deparaffinized,
and treated with 0.4% pepsin (2500 FIP-Ug-1,
Merck, Darmstadt, West Germany) in 0.01 N HC1
for 1 h at 37°C. Frozen sections were postfixed for
10min in acetone. All sections were then incubated
in 0.5% hydrogen peroxide in methanol for 30min
to block endogenous peroxidase, incubated with
non-imune horse serum, diluted 1:20, and then
reacted with the monoclonal antibody 1116NS 19-9
supernatant, diluted 1:50. Bound antibody was
visualized by the avidin-biotin complex assay (ABC)
(Vectastain, Vector Laboratories, Burlingame, CA):
the sections were successively treated with biotiny-
lated anti-mouse immunoglobulin antiserum,
avidin, and biotinylated horseradish peroxidase
complex. Phosphate-buffered saline (PBS) washes
followed each incubation. Finally, sections were
incubated with 3-amino-9-ethyl-carbazole (AEC)
and hydrogen peroxide and some specimens were
counterstained with hematoxylin.
The effect of enzyme pretreatment was tested in a
series where CA 19-9 positive sections were
pretreated, either with 0.4% pepsin in 0.01 N HCl,
with 0.01 N HCl only, with 0.1% trypsin, or with
PBS. Various incubation times were tested.
Staining with normal mouse serum and with the
monoclonal antibody against Uukuniemi virus
served as negative controls. The sialic acid residue
of the CA 19-9 antigen was removed in a control
series using Vibrio cholera neuraminidase
(Behringwerke AG, Marburg, West Germany).
Incubation of the sections for 2h with concentra-
tions of neuraminidase higher than 0.1 Uml- I
abolished the staining. Two known positive pan-
creatic adenocarcinoma specimens served as positive
controls in each staining series.
For the Lewisa and Lewisb stainings an indirect
immunoperoxidase technique was used. The steps
until the incubation with the non-immune serum
were performed as described above. The sections
were incubated with non-immune rabbit serum,
diluted 1:20, the Lewisa or Lewisb antibody,
diluted 1:5, and then with rabbit anti-mouse
peroxidase conjugate (Dako, Copenhagen,
Denmark), diluted 1:50. Washings in PBS followed
each step and finally the sections were exposed to
AEC and hydrogen peroxide.
Serum concentration ofCA 19-9
Sera from 30 patients were available for measure-
ment of the CA 19-9 level by a radioimmunoassay
(Centocor, Malvern, PA, USA).
Results
Sensitivity ofthe CA 19-9 staining
The optimal staining reaction was obtained after
pepsin treatment for 1 h of formalin-fixed paraffin
block sections (Figure 1). None of the negative
specimens became positive after pepsin treatment.
Staining of frozen sections showed a similar
pattern, but the reaction was weaker.
Normalpancreas
In 23 out of 29 specimens (79%) a positive staining
for CA 19-9 was seen in the apical border of ductal
cells (Table I). A positive reaction was typically
seen in some ducts only, and it was often weak.
Large ducts were more often positive and stained
more strongly than small ducts. Normal pancreas
and normal pancreatic tissue adjacent to chronic
pancreatitis or carcinoma showed the same staining
pattern and intensity. Acinar structures and
Langerhans' islets were always negative for CA 19-
9 (Figure 1).
Chronic pancreatitis
In 22 out of 23 cases (96%) ducts were positive for
CA 19-9 (Table I). The staining pattern was similar
to that seen in large ducts of normal pancreas, but
the staining intensity was stronger in chronic
pancreatitis. Intraluminal mucus stained positively.
There was no difference between the staining
pattern and intensity of specimens from pancreata
with chronic pancreatitis only and four cases with
chronic pancreatitis adjacent to a carcinoma.
Centroacinar and acinar cells were negative
(Figure 2).
Acute pancreatitis
Eleven of 12 cases (92%) stained positively
(Table I). In 9 cases the staining was intense and
uniformly distributed in small terminal ducts and
centroacinar cells, whereas only a part of the largeCA 19-9 IN PANCREATIC LESIONS 191
Figure 1 Normal pancreas, A. Haematoxylin-eosin, B. Immunoperoxidase
without pepsin treatment, C. same as B after pepsin treatment ( x 220).
staining with 1116NS 19-9,
Table I Tissue expression of CA 19-9 in benign and malignant pancreatic lesions
Tissue staininga
No
Histology ofspecimens - + + + + +
Normal pancreas 29 6 23
Acute pancreatitis 12 1 2 5 4
Chronic pancreatitis 23 1 10 11 1
Well to moderately differentiated
adenocarcinoma 46 7 3 12 24
Poorly differentiated and
anaplastic carcinoma 14 5 5 2 2
Cystic tumours
Serous cystadenoma 3 3
Mucinous cystadenoma 5 1 4
Cystadenocarcinoma 3 3
Islet cell tumours
Benign 6 6
Malignant 4 4
aArbitrary scoring of distribution and intensity.
ducts were positive for CA 19-9. Acinar cells were
always negative. In two cases a few small ducts
only stained positively. Thus, in most cases, the
staining pattern clearly differed from that seen in
chronic pancreatitis and in normal pancreata
(Figure 3).
Well to moderately differentiated adenocarcinoma
Thirty-nine out of 46 (85%) tumours expressed
CA 19-9 (Table I). In most cases a cytoplasmic
staining was observed. Frequently, the staining was
focal. The secreted mucus was intensely stained. In
well differentiated areas the positivity was pre-
dominantly seen in the brush border, while in
moderately differentiated areas the staining was
more diffuse. In many specimens with intense staining
a diffuse positivity of the surrounding matrix was
seen as well (Figure 4).192 C. HAGLUND et al.
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Figure 2 Chronic pancreatitis, A. Haematoxylin-eosin,
B. Immunoperoxidase staining with 1116NS 19-9
(x 220).
Figure 4 Well differentiated ductal adenocarcinoma
of the pancreas, A. Haematoxylin-eosin, B. Immuno-
peroxidase staining with 1116NS 19-9 ( x220).
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Figure 3 Acute pancreatitis, A. Haematoxylin-eosin,
B. Immunoperoxidase staining with 1116NS 19-9,
counterstained with haematoxylin ( x 400).
Poorly differentiated and anaplastic carcinomas
Six out of 9 poorly differentiated adenocarcinomas
and three out of five anaplastic carcinomas
expressed CA 19-9 (Table I). In poorly differen-
tiated adenocarcinomas the number of positive cells
was smaller than in well differentiated carcinomas
(Figure 5), and in anaplastic carcinomas cells were
stained only occasionally (Figure 6).
Cystic tumours
All five mucinous cystadenomas and three cyst-
adenocarcinomas were strongly positive (Table I).
Especially the mucus stained intensely (Figure 7).
Figure 5 Poorly differentiated ductal adenocarcinoma
of the pancreas, A. Haematoxylin-eosin, B. Immuno-
peroxidase staining with 1116NS 19-9 (x 220).
The staining pattern was the same as in the ductal
adenocarcinomas, but even more intense. Three
serous cystadenomas were negative for CA 19-9
(Table I).
Islet cell tumours
All six benign and four malignant islet cell tumours
were negative for CA 19-9 (Table I).
Staining ofLewis blood group substances
The eleven CA 19-9 negative adenocarcinomas and
anaplastic carcinomas were stained with the Lewisa
and Lewisb antibodies. Four cases were positive for
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Figure 6 Anaplastic carcinoma of the pancreas, A.
Haematoxylin-eosin, B. Immunoperoxidase staining
with 1116NS 19-9 ( x400).
differentiated adenocarcinoma and one anaplastic
carcinoma the serum concentration was high,
although the tissue reaction was negative. All
cystadenocarcinomas were intensely stained and the
patients had clearly elevated serum CA 19-9 levels,
whereas the islet cell carcinomas were tissue
negative and had a normal serum level.
Discussion
Immunoperoxicdase staining is a reliable method of
demonstrating the CA 19-9 antigen in formalin-
fixed specimens. In earlier reports the staining has
been performed without pretreatment (Atkinson et
al., 1982) or after incubation with trypsin (Arends
et al., 1983). We showed that the optimal staining
result is obtained after treatment of the specimens
with pepsin. However, the CA 19-9 staining
positivity could also be seen without pretreatment
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In our material many ducts of normal pancreatic
tissue adjacent to pathological lesions stained
positively for CA 19-9, while acini were negative.
The expression of the CA 19-9 antigen by cells of
the ducts of normal pancreas has been
demonstrated earlier (Atkinson et al., 1982; Arends
et al., 1983). Thus, it is not surprising that
carcinomas of ductal origin express the CA 19-9
antigen. The fact that the staining was more intense
in pancreatitis than in normal ducts and clearly
strongest in well differentiated carcinomas can be
explained by accumulation of the antigen in the
tissue due to obstruction of pancreatic ducts by
these lesions. On the other hand the ifntense staining
of the mucus and staining of intracytoplasmic
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Figure 7 Mucinous cystadenoma of the pancreas, A.
Haematoxylin-eosin, B. Immunoperoxidase staining
with l1l6NS 19-9(x220).
Lewisb and one case for both Lewisa and Lewisb.
Six cases were both CA 19-9 and Lewis negative.
The positivity for the Lewis antigens was seen in
the apical border of glandular structures, and also
as a focal intracytoplasmic staining of some tumour
cells.
Correlation between tissue staining and serum
concentration
In well to moderately differentiated ductal adeno-
carcinomas an elevated serum CA 19-9 concen-
tration was always associated with a positive tissue
staining (Table II). A positive tissue reaction was
seen in some patients in spite of a low serum level,
especially if the tumour was small. In one poorly
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adenocarcinomas, and especially of cystadeno-
carcinomas speak for an increased production of
the CA 19-9 antigen by these tumours, which
agrees with the elevated serum levels found in most
patients with pancreatic cancer (Jalanko et al.,
1984; Haglund et al., 1986). All serous
cystadenomas were negative. The intense staining of
CA 19-9 in mucinous tumours, especially in the
intraluminal mucus, is in analogy with the
observation, that the circulating CA 19-9 antigen is
found in the mucin fraction (Magnani et al., 1983).
Normal pancreatic islets are negative for CA 19-9,
and it seems that islet cell tumours do not express
CA 19-9 in tissue.
The expression of the CA 19-9 antigen requires
expression of the Lewis blood group gene which is
lacking in 5% of the population. In our material
the proportion of CA 19-9 negative carcinomas was
higher. Therefore we stained all eleven CA 19-9
negative adenocarcinomas and anaplastic carci-
-1- - . I
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Table II CA 19-9 in tissue and serum of patients with pancreatic cancer
Histology Patient no. Tissuea Serumb
Small, well to moderately differentiated 1 + + + 1600
adenocarcinoma 2 + + + 210
3 +++ 45
4 - 36
5 + 35
6 +++ 34
Large, well to moderately differentiated 7 + + + 7900
adenocarcinoma 8 + + 4800
9 +++ 910
10 ++ 705
11 +++ 595
12 + + 580
13 +++ 500
14 +++ 485
15 ++ 300
16 +++ 81
17 +++ 76
18 - 21
19 + <6.2
Poorly differentiated and 20 + + + 12500
anaplastic carcinoma 21 + 1200
22 - 1200
23 +++ 915
24 - 120
25 + <6.2
Cystadenocarcinoma 26 + + + 4100
27 +++ 3100
28 +++ 565
Islet cell carcinoma 29 - 19
30 - 8
aArbitrary scoring of distribution and intensity.
bConcentration in unitsml-1, cut-off level 37Uml 1.
nomas with Lewisa and Lewis" antibodies. Five of
these carcinomas were Lewisb positive and one
was also Lewisa positive. The expression of both
Lewisa and Lewisb antigens in some Lewisb patients
has earlier been demonstrated in normal and
carcinomatous pancreatic, gastric and colonic
tissues (Ernst et al., 1984; Sipponen & Lindgren,
submitted). Two patients, that were both CA 19-9
and Lewis negative, had elevated CA 19-9 values in
serum. Thus it seems that Lewis blood group
antigens, like the CA 19-9 antigen, are not
expressed by all tumour cells.
In large, well to moderately differentiated adeno-
carcinomas and cystadenocarcinomas there was a
good correlation between the serum concentration
and the tissue expression of CA 19-9. All tumours
associated with a high serum level showed an
intense tissue reaction. A high serum level is not
always associated with a strong staining, as seen in
poorly differentiated or anaplastic carcinomas.
These are often widely disseminated by the time of
diagnosis, which can explain the elevated serum
levels seen in patients with immunohistochemically
negative or weakly stained tumours. On the other
hand, a normal serum level does not exclude a
positive tissue staining, as seen in patients with
small tumours of the pancreas.
The CA 19-9 serum test by radioimmunoassay
has proven to be a valuable tumour marker in the
differential diagnosis between pancreatic cancer and
benign pancreatic diseases (Jalanko et al., 1984;
Haglund et al., 1986). In tissue the expression of
CA 19-9 seems to correlate with the degree of
differentiation of pancreatic carcinomas, but is of
limited use in differentiating benign from malignant
pancreatic lesions. However, the tissue expression
of the CA 19-9 antigen in most tumours gives a
basis for trials with immunoscintigraphy forCA 19-9 IN PANCREATIC LESIONS 195
localization purposes. In addition, a positive
CA 19-9 staining, also when the preoperative
CA 19-9 level is normal, can tell the clinician,
whether a postoperative monitoring by regular
serum CA 19-9 assays might be useful.
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